United States neurostimulation device market

The US neurostimulation device market will be driven by continuous product innovation, including product launches and device improvements targeting expanded indications. Strategic market acquisitions—such as Boston Scientific acquiring Axonics—rapid uptake of novel technologies, and rising availability of products such as closed-loop SCS devices and minimally invasive tibial nerve stimulation devices will also contribute to this growth. However, the availability of alternative noninvasive treatment options and strict indication-specific requirements for reimbursement may limit the growth of the US neurostimulation market to some extent.
Read our Market snapshot to access data and analysis on the state of the market for neurostimulation devices in the US from 2019 through 2033.
